Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system.
Epstein-Barr virus (EBV) targeted therapeutic strategies for viral associated malignant diseases have received only perfunctory consideration, first, because latent herpesviruses have been intractable to antiviral chemotherapy and, second, because the role EBV has in maintenance of the malignant cell phenotype has been uncertain. Two patients with EBV related primary central nervous system lymphoma (PCNSL) in the setting of advanced AIDS, were treated with low dose hydroxyurea based on in vitro anti-EBV activity. The responses obtained here suggest the promise of antiviral approaches in select cancers.
Slobod
K S
KS
Taylor
G H
GH
Sandlund
J T
JT
Furth
P
P
Helton
K J
KJ
Sixbey
J W
JW
D000293:Adolescent; D000328:Adult; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000821:virology; D020031:Epstein-Barr Virus Infections / Q000188:drug therapy* / Q000821:virology; D005260:Female; D004854:Herpesvirus 4, Human / Q000187:drug effects*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy* / Q000821:virology; D008279:Magnetic Resonance Imaging; D008297:Male
D006918:Hydroxyurea